Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: A retrospective analysis of 40 dogs

2017 ◽  
Vol 16 (1) ◽  
pp. E194-E201 ◽  
Author(s):  
S. J. Moirano ◽  
S. F. Lima ◽  
K. R. Hume ◽  
E. M. Brodsky
Keyword(s):  
Survival Time ◽  
Retrospective Analysis ◽  
Systemic Mastocytosis ◽  
Prognostic Features

Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy

2007 ◽  
Vol 25 (6) ◽  
pp. 675-681 ◽  
Author(s):  
David B. Agus ◽  
Christopher J. Sweeney ◽  
Michael J. Morris ◽  
David S. Mendelson ◽  
Douglas G. McNeel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Time ◽  
Retrospective Analysis ◽  
Single Agent ◽  
Growth Factor Receptor ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Prognostic Features ◽  
Castration Resistant ◽  
Epidermal Growth

Purpose Pertuzumab represents a new class of targeted anticancer agents, human epidermal growth factor receptor (HER) dimerization inhibitors. The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy. Patients and Methods Patients received pertuzumab every 3 weeks. All castration-resistant patients had experienced progression after at least one taxane-based regimen. Patients received a loading dose of 840 mg pertuzumab (cycle 1) followed by 420 mg for subsequent cycles. The primary end point was overall response and safety. A separate retrospective analysis of actual survival time versus predicted survival time for a patient population with comparable prognostic features was performed. Results Patients were enrolled (N = 42) and treated (n = 41). No patients had complete or partial response (as defined by Response Evaluation Criteria in Solid Tumors Group or ≥ 50% decline in prostate-specific antigen). Of 30 efficacy-assessable patients, five had stable disease (SD) for at least 23 weeks; one of five had SD for 36 weeks. Pertuzumab was well tolerated; diarrhea was the most common adverse effect (61.0%, grades 1 to 3). Retrospective analysis of survival using a validated nomogram suggested that survival was prolonged with pertuzumab treatment, compared with historic controls with similar baseline prognostic features. Conclusion Pertuzumab was well tolerated and resulted in no objective responses, but several patients had SD more than 23 weeks from a heavily pretreated population. Retrospective analysis suggested prolonged median survival time with pertuzumab compared with historical controls. Thus, inhibition of HER dimerization may have clinical utility in CRPC patients.

scholarly journals RETROSPECTIVE ANALYSIS OF LEPTOSPIROSIS MORBIDITY IN IVANO-FRANKIVSK REGION (EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS)

2020 ◽  
Vol 73 (7) ◽  
pp. 1397-1401
Author(s):  
Oleksandra Ya. Pryshliak ◽  
Tetiana O. Nikiforova ◽  
Zoriana R. Tylishchak ◽  
Oleksandr P. Boichuk ◽  
Nadiya V. Vaskul ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Medical Records ◽  
Clinical Characteristics ◽  
Clinical Observation ◽  
State Enterprise ◽  
Winter Period ◽  
Prognostic Features ◽  
The Past ◽  
Regional Laboratory ◽  
High Virulence

The aim: To perform a retrospective analysis of leptospirosis morbidity in Ivano-Frankivsk region, to give the etiological characteristics of leptospirosis according to clinicallaboratory parameters, to determine the peculiarities of the course, prognostic features. Materials and methods: Data of the State Enterprise “Ivano-Frankivsk Regional Laboratory Center of the Ministry of Health of Ukraine”, reports and abstracts of medical records of the Regional Clinical Infectious Diseases Hospital for 2009-2018 were used. Clinical observation of patients, analysis of general-clinical, biochemical, and serological indices were carried out. Results: The leptospirosis morbidity in Ivano-Frankivsk region during 2009-2018 was higher than in general in Ukraine. Activation of foci of leptospirosis L. pomona and grippotyphosa in 2009-2013, decrease of L. grippotyphosa and increase of L. pomona foci and “new” L. autumnalis, australis, bataviae, cynopteri in 2014-2018 were noted. The emergence of leptospirosis L. autumnalis, which had a high virulence and caused a severe course, was noted. Conclusions: The leptospirosis morbidity in the Ivano-Frankivsk region over the past 10 years has exceeded the incidence in Ukraine and varied within 0.62-2.2 per 100,000. During the last 5 years, the serological structure has changed: L. pomona (27.7%) prevailed, L. grippotyphosa decreased (2.1%), L. bataviae and cynopteri, autumnalis increased (by 8.5%). Seasonality is shifted in the autumn-winter period (November-February) (L. grippotyphosa, australis, pomona, canicola). According to forecasts, leptospirosis induced by L. autumnalis was most adverse. Leptospiroses of serogroups L. australis, bataviae, cynopteri had a mild course, there were fewer complications.

The Performance of First Molar Orthodontic Bands Cemented with Glass Ionomer Cement—A Retrospective Analysis

1992 ◽  
Vol 19 (3) ◽  
pp. 215-220 ◽  
Author(s):  
D. T. Millett ◽  
P. H. Gordon
Keyword(s):  
Survival Time ◽  
Retrospective Analysis ◽  
Orthodontic Treatment ◽  
Glass Ionomer Cement ◽  
Glass Ionomer ◽  
Factors Influencing ◽  
Permanent Molars ◽  
First Permanent Molars ◽  
Ionomer Cement

Various factors influencing the survival time of orthodontic bands cemented to first permanent molars with glass ionomer cement (KETAC-CEM, Espe) have been investigated. Data on 513 patients with 1424 first molar bands who completed orthodontic treatment between 1985 and 1989 inclusive were analysed. Performance of bands cemented to first permanent molars varied according to the operator, age of the patient and treatment mechanics, but not according to the sex of the patient or quadrant in which the band was fitted.

Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3554-3554
Author(s):  
Brunella Di Stefano ◽  
Maria Alessandra Calegari ◽  
Michele Basso ◽  
Armando Orlandi ◽  
Alessandra Boccaccino ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Survival Data ◽  
Kinase Activity ◽  
Radical Resection ◽  
Braf V600e ◽  
Lower Grade ◽  
Braf Mutations ◽  
Clinicopathologic Characteristics ◽  
Prognostic Features ◽  
Resection Of Metastases

3554 Background: Recently, 3 classes of BRAF MTs have been described. BRAF V600 MTs, which identify mCRC with poor prognosis and not benefitting from anti-EGFR drugs, belong to class 1. Class 2 and 3 include BRAF non-V600 MTs, which occur in about 1-2% mCRC and are associated to favourable prognosis and specific clinicopathologic features. Class 2 and 3 differ in kinase activity and sensitivity to anti-EGFR: class 2 are activated and RAS-independent MTs; class 3 are kinase-dead and sensitive to inhibition of This study aims to retrospectively evaluate features and prognostic role of rare BRAF non-V600 compared to BRAF V600E MTs in mCRC pts treated at 2 Italian Institutions. Methods: mCRC pts harboring BRAF MTs, assessed by means of NGS, pyrosequencing or RT-PCR, treated between Jan-13 and Dec-18 at 2 Italian Institutions, were retrospectively analyzed. Clinico-pathological and treatment characteristics and survival data were collected. Results: 55 pts bearing BRAF MTs were identified. Of those, 46 (84%) harbored a V600E and 9 (16%) a non-V600 MT. Within the non-V600 group, 3 MTs (K601E, G469A, G469R) belonged to class 2, while 5 MTs (G466E, G466A, 2 D594G, D594N), belonged to class 3. One pt harboured a T599I MT, whose kinase activity is unknown. Compared to BRAF V600E mCRC, BRAF non-V600 mCRC were more frequently left-sided ( p .017) and displayed a lower grade ( p .045). In addition, non-V600 mCRC pts had a lower tumor burden (involving one metastatic site) ( p .026) and underwent more frequently to resection of metastases with radical intent (77.7 vs 18%; p .000175). mOS was significantly longer in the non-V600 compared to the V600E group (61.3 vs 20.4 m; HR 0.41, 95%CI 0.18-0.93; p .05). No difference in activity and efficacy of anti-EGFR agents was observed between class 2 and 3. Conclusions: Despite the small size of our retrospective analysis, the results were consistent with previous evidences. BRAF non-V600 MTs identified a subgroup of mCRC, differing both in terms of clinicopathologic characteristics and prognosis from BRAF V600 mCRC. Interestingly, the better prognostic features allowed more frequently radical resection of metastases, positively impacting on survival.

scholarly journals Efficacy of Omalizumab in Indolent Systemic Mastocytosis

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Calum Slapnicar ◽  
Martina Trinkaus ◽  
Lisa Hicks ◽  
Peter Vadas
Keyword(s):  
Mast Cells ◽  
Allergic Asthma ◽  
Retrospective Analysis ◽  
Chronic Urticaria ◽  
Systemic Mastocytosis ◽  
Heterogeneous Group ◽  
Internal Organs ◽  
Indolent Systemic Mastocytosis

Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited. Methods. A retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St. Michael’s Hospital between 2009 and 2018 is described. Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease. Results. Of the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions. Significant improvement in cutaneous symptoms was also observed. Conclusion. These data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies.

scholarly journals Retrospective analysis of survival time in malignant pleural effusion requiring IPC insertion

2017 ◽  
Author(s):  
Rachelle Asciak ◽  
Rob Hallifax ◽  
Rebecca Shakir ◽  
Nikolaos Kanellakis ◽  
Ioannis Psallidas ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Survival Time ◽  
Retrospective Analysis ◽  
Malignant Pleural Effusion

scholarly journals Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Pai Peng ◽  
Jiang-Yuan Chen ◽  
Yun-Tao Han ◽  
Xin Chen ◽  
Hong-Yuan Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Survival Time ◽  
Retrospective Analysis ◽  
Median Survival ◽  
Median Survival Time ◽  
Seer Database ◽  
Primary Surgery ◽  
Surgical Group

Abstract Background It was controversial to operate on the primary site of breast cancer (BC) with bone metastasis only. We investigated the impact of surgery on BC patients with bone metastases via a SEER database retrospective analysis. Methods A total of 2917 BC cases with bone metastasis, first diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and Results Database (SEER) of National Cancer Institute were selected. We assessed the effect of different surgical procedures on survival and prognosis. Results Compared with the non-surgical group, the primary tumor surgical group showed longer median survival time (χ2 = 146.023, P < 0.001), and the breast-conserving subgroup showed the highest median survival time of 70 months (χ2 = 157.117, P < 0.001). Compared with the non-surgery group, the median overall survival (OS) of primary surgery group was longer (HR = 0.525, 95%CI = 0.467–0.590, P < 0.001), and the breast-conserving subgroup showed the longest median operative OS (HR = 0.394, 95%CI = 0.325–0.478, P < 0.001). Conclusion This study showed that primary surgery could improve the median survival time and OS of BC patients with bone metastasis. Moreover, under the condition of low tumor burden, breast conserving surgery was a better choice.

Deletion 5q in WHO-Defined Myeloproliferative Neoplasms: A Clinicopathological Description.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2552-2552
Author(s):  
Rafael Santana-Davila ◽  
Ayalew Tefferi ◽  
Shernan G. Holtan ◽  
Rhett P. Ketterling ◽  
Ryan A. Knudson ◽  
...  
Keyword(s):  
Overall Survival ◽  
Platelet Count ◽  
Systemic Mastocytosis ◽  
Myeloproliferative Neoplasms ◽  
Hypereosinophilic Syndrome ◽  
Primary Myelofibrosis ◽  
Hemoglobin Level ◽  
World Health ◽  
Prognostic Features ◽  
Chronic Eosinophilic Leukemia

Abstract Background: Deletion 5q is a lenalidomide-sensitive cytogenetic abnormality seen usually in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In the current study, we looked into the occurrence and clinicopathologic correlates of del(5q) in myeloproliferative neoplasms (MPNs) defined according to the World Health Organization (WHO) criteria. Methods: Patients with del(5q)-positive MPN were identified through database query involving over 2000 patients with myeloproliferative neoplasms (MPD) including no less than 500 patients with primary myelofibrosis (PMF), 600 patients with essential thrombocytosis (ET), 500 patients with polycythemia vera (PV), and the remaining comprised of patients with molecularly-undefined chronic eosinophilic leukemia, hypereosinophilic syndrome, systemic mastocytosis (SM), chronic neutrophilic leukemia, and “MPN, unclassifiable”. Results: A total of 23 patients with del(5q) were identified (12 at time of initial diagnosis), suggesting an overall prevalence rate of 1%. A central pathological review was conducted to confirm the diagnosis in each instance. Specific diagnoses included PMF (n=14; estimated prevalence of 3%), MPN, unclassifiable (n=4), PV (n=2), ET (n=1), post ET-myelofibrosis (n=1) and SM (n=1). Del(5q) was a sole abnormality in 5 patients, accompanied by one other abnormality in 6 patients, and part of a complex karyotype in 12 patients. The most common breakpoint was q13q33 (n=10) followed by q15q33 (n=6). Based on sample size adequacy, we focused on del(5q)-positive PMF patients and compared their bone marrow histological and clinical features with their del(5q)-negative counterparts seen at the Mayo Clinic during the same period of time (n=311). There was no difference in gender or age distributions. Histopathological review did not show the typical tight clusters of megakaryocytes seen in classic PMF. The megakaryocytes were not the predominate feature of the biopsy, in general were less lobulated and smaller in size, and had a higher grade of fibrosis (med = 3+) than classic PMF. Furthermore, del(5q)-positive PMF patients presented with significantly lower hemoglobin level (p=0.0009) and platelet count (p=0.0003). The percentage of patients presenting with a hemoglobin level of &lt; 10 g/dL or a platelet count of &lt; 100 × 109/L were 70% and 92% in del(5q)-positive patients as opposed to 43% and 18% in del(5q)-negative patients. However, the presence of del(5q) did not significantly affect either overall survival (Figure) or leukemic transformation in PMF (14% vs 9%). Conclusions: Del(5q) is generally rare in MPNs but might occur in as much as 3% of patients with PMF. The presence of del(5q) does not appear to affect overall survival in PMF despite its clustering with adverse prognostic features for the disease including anemia and thrombocytopenia. Finally, megakaryocyte morphology and distribution in del(5q)-associated PMF are characteristically different from classic PMF. Figure Figure

Sign in / Sign up

Export Citation Format

Share Document